These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 35788882

  • 1. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X, Xu J, Zhong S, Zou J, Cheng Z, Ding Z, Zhou X.
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [Abstract] [Full Text] [Related]

  • 2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [Abstract] [Full Text] [Related]

  • 3. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ, Zhao WL, Wei CG, Zhang CY, Wen R, Gu YF, Li MJ, Zhang YY, Wu JF, Li X, Shen JK.
    Zhonghua Yi Xue Za Zhi; 2017 Dec 19; 97(47):3693-3698. PubMed ID: 29325321
    [Abstract] [Full Text] [Related]

  • 4. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB, Wei CG, Zhang YY, Pan P, Dai GC, Tu J, Shen JK.
    Biomed Res Int; 2021 Dec 19; 2021():3995789. PubMed ID: 34671673
    [Abstract] [Full Text] [Related]

  • 5. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D, Gromicho A, Dias J, Bastos S, Maciel RM, Sabença A, Xambre L.
    Arch Ital Urol Androl; 2023 Dec 20; 95(4):11830. PubMed ID: 38117217
    [Abstract] [Full Text] [Related]

  • 6. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
    Wang L, Luo Y, Liu T, Deng M, Huang X.
    Int Urol Nephrol; 2023 Jul 20; 55(7):1659-1664. PubMed ID: 37171702
    [Abstract] [Full Text] [Related]

  • 7. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C, Liu SL, Wang ZX, Yu K, Feng CX, Ke Z, Wang L, Zeng XY.
    Asian J Androl; 2018 Jul 20; 20(5):459-464. PubMed ID: 29667616
    [Abstract] [Full Text] [Related]

  • 8. Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients.
    Ryoo H, Kang MY, Sung HH, Chang Jeong B, Seo SI, Jeon SS, Lee HM, Jeon HG.
    Prostate Int; 2020 Sep 20; 8(3):125-129. PubMed ID: 33102394
    [Abstract] [Full Text] [Related]

  • 9. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, Shariat SF, Pinker K, Helbich TH, Baltzer PAT.
    Clin Radiol; 2020 Feb 20; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [Abstract] [Full Text] [Related]

  • 10. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
    Massanova M, Vere R, Robertson S, Crocetto F, Barone B, Dutto L, Ahmad I, Underwood M, Salmond J, Patel A, Celentano G, Bhatt JR.
    Curr Urol; 2023 Sep 20; 17(3):147-152. PubMed ID: 37448611
    [Abstract] [Full Text] [Related]

  • 11. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
    Nguyen TA, Fourcade A, Zambon A, Saout K, Deruelle C, Joulin V, Tissot V, Doucet L, Rozet F, Fournier G, Valeri A.
    Urol Oncol; 2023 Aug 20; 41(8):354.e11-354.e18. PubMed ID: 37391283
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM, Shang JW, Dong L, Liang LH, Zhao RZ, Liang C, Wang SQ, Xia W, Cheng G, Hua LX.
    Zhonghua Zhong Liu Za Zhi; 2023 Nov 23; 45(11):942-947. PubMed ID: 37968079
    [Abstract] [Full Text] [Related]

  • 13. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X, Chen X, Peng P, Zhou H, Hong Y, Zhu C, Lu L, Xie S, Zhang S, Long L.
    BMC Urol; 2024 Feb 16; 24(1):40. PubMed ID: 38365673
    [Abstract] [Full Text] [Related]

  • 14. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY.
    J Cancer Res Clin Oncol; 2018 May 16; 144(5):987-995. PubMed ID: 29504080
    [Abstract] [Full Text] [Related]

  • 15. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
    Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, Chen J, Yang W, Ma S, Wu P, Jing Y, Wen W, Kang F, Wang J, Qin W.
    Prostate Cancer Prostatic Dis; 2024 Jun 16; 27(2):288-293. PubMed ID: 38160227
    [Abstract] [Full Text] [Related]

  • 16. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
    Yang S, Zhao W, Tan S, Zhang Y, Wei C, Chen T, Shen J.
    Transl Androl Urol; 2020 Jun 16; 9(3):1252-1261. PubMed ID: 32676408
    [Abstract] [Full Text] [Related]

  • 17. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
    Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Nie L, Qiu S, Liu ZH, Jin K, Li JK, Xiong XY, Yang L, Wei Q.
    Asian J Androl; 2022 Jun 16; 24(6):615-619. PubMed ID: 35532555
    [Abstract] [Full Text] [Related]

  • 18. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml-1 to 10 ng ml-1.
    Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Qiu S, Liu ZH, Yang L, Wei Q.
    Asian J Androl; 2023 Jun 16; 25(4):492-498. PubMed ID: 36571328
    [Abstract] [Full Text] [Related]

  • 19. Unlocking Precision Enhancing Prostate Cancer Detection and Reducing Unnecessary Biopsies with Combined Prostate-Specific Antigen Density and PI-RADS Score.
    Hamidi N, Uzel T, Demirci A, Basar H.
    J Coll Physicians Surg Pak; 2024 Oct 16; 34(10):1205-1210. PubMed ID: 39410690
    [Abstract] [Full Text] [Related]

  • 20. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C, Oz DK, Oktar A, Suer E, Ozden E, Haliloglu N, Gulpinar O, Gokce MI, Gogus C, Baltaci S.
    Clin Genitourin Cancer; 2024 Jun 16; 22(3):102071. PubMed ID: 38555682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.